HC Wainwright Boosts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $94.00

ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price objective increased by HC Wainwright from $87.00 to $94.00 in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2024 earnings at $0.75 […]

Leave a Reply

Your email address will not be published.

Previous post Bunzl’s (BNZL) “Buy” Rating Reiterated at Shore Capital
Next post SolarEdge Technologies (NASDAQ:SEDG) Price Target Cut to $25.00